Drug intelligence / Profile preview

GD-19

Development stage: Preclinical
Lead developer: Tianjin Gudui Biopharmaceutical Technology
Modality: Small Molecules

Overview

GD-19 is a small molecule drug candidate currently in preclinical development by Gudui BioPharma for the treatment of pain. It acts as a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme that plays a critical role in the biosynthesis of prostaglandins, which are key mediators of inflammation and pain signaling. By specifically targeting the COX-2 isoform while avoiding significant inhibition of COX-1, GD-19 aims to provide effective analgesia with a reduced risk of the gastrointestinal and renal side effects typically associated with non-selective nonsteroidal anti-inflammatory drugs (NSAIDs).

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on GD-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GD-19.

Explore the full profile